Literature DB >> 1890305

The effects of IL-1, IL-2, and tumor necrosis factor on polymorphonuclear leukocyte Fc gamma receptor-mediated phagocytosis. IL-2 down-regulates the effect of tumor necrosis factor.

M M Moxey-Mims1, H H Simms, M M Frank, E Y Lin, T A Gaither.   

Abstract

It has been reported that the Fc gamma R-mediated phagocytic activity of polymorphonuclear leukocytes (PMN) from patients with acute bacterial infections is markedly enhanced when compared with healthy controls. Inasmuch as several potent cytokines are known to be involved in inflammatory and infectious processes, we studied the effects of three such cytokines (IL-1 beta, IL-2, and TNF-alpha) on normal PMN Fc gamma R-mediated phagocytosis. IL-1 beta and TNF alpha both caused a significant increase in the ingestion of EIgG by adherent PMN. In combination, IL-1 beta and TNF-alpha had an additive effect, even when each was used at its optimal concentration. In contrast to the enhancing effects mediated by IL-1 beta and TNF-alpha, IL-2 alone had no significant effect on PMN phagocytosis. Notably, however, IL-2 at a concentration of 10(4) U/ml partially inhibited TNF-alpha-mediated enhancement of phagocytosis by decreasing TNF binding to the PMN cell surface. This inhibitory effect of IL-2 on TNF was reversed by anti-IL-2 antibody and mAb directed against the low affinity IL-2R (anti-Tac), whereas mAb directed against the intermediate affinity receptor (mik-beta 1) had no such effect. These findings may have important physiologic implications, because patients receiving IL-2 therapy have been shown to have increased susceptibility to infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1890305

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Neutrophils in a mouse model of autoantibody-mediated arthritis: critical producers of Fc receptor gamma, the receptor for C5a, and lymphocyte function-associated antigen 1.

Authors:  Paul A Monach; Peter A Nigrovic; Mei Chen; Hanno Hock; David M Lee; Christophe Benoist; Diane Mathis
Journal:  Arthritis Rheum       Date:  2010-03

Review 2.  Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

3.  Alterations of bacterial clearance induced by endotoxin and tumor necrosis factor.

Authors:  T Koch; H P Duncker; R Axt; H G Schiefer; K van Ackern; H Neuhof
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

4.  Critical role of peripheral blood phagocytes and the involvement of complement in tumour necrosis factor enhancement of passive collagen-arthritis.

Authors:  R A Fava; C Gates; A S Townes
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

5.  Impairment of bacterial clearance induced by norepinephrine infusion in rabbits.

Authors:  T Koch; S Heller; K van Ackern; H G Schiefer; H Neuhof
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

6.  Tumor necrosis factor alpha binding to bacteria: evidence for a high-affinity receptor and alteration of bacterial virulence properties.

Authors:  G Luo; D W Niesel; R A Shaban; E A Grimm; G R Klimpel
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

7.  Identification and biochemical characterization of human plasma neutrophil inhibitor in vitro.

Authors:  Y Abe; Y Kashu; T Lee; M Sato; K Kimura; S Kimura
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

8.  Proinflammatory stimuli enhance phagocytosis of apoptotic cells by neutrophil granulocytes.

Authors:  Lars Hellberg; Sabrina Fuchs; Christoph Gericke; Arup Sarkar; Martina Behnen; Werner Solbach; Tamás Laskay
Journal:  ScientificWorldJournal       Date:  2011-11-15

Review 9.  Neutrophil-Mediated Phagocytosis of Staphylococcus aureus.

Authors:  Kok P M van Kessel; Jovanka Bestebroer; Jos A G van Strijp
Journal:  Front Immunol       Date:  2014-09-26       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.